Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis and placental secretomics.
Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization. Placental organoid model can be used in the study of placental pathophysiology. In in particular, it provides a personalized model for sartorial in vitro evaluation of personalized therapeutic efficacy of different pharmacological therapies. In particular, with placental organoid it is possible to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis and placental secretomics.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placenta organoids treatment | Drug | Placenta organoids in vitro treatment with heparin, aspirin, IVIG, filgrastim and metformin |
| Measure | Description | Time Frame |
|---|---|---|
| Development of placental 3D organoid model | Morphological characteristics of placental 3D organoids successfully developed from placentas obtained from full-term physiological pregnancies and pathological conditions (abortion, preeclampsia, preterm delivery). Assessment Parameters: Organoid formation efficiency (%) | From the date of caesarean section until the development of placental organoids, assessed up to 36 months. |
| Characterization of placental 3D organoid model | Assessment of cell viability (live/dead staining) | From the date of caesarean section until the development of placental organoids, assessed up to 36 months. |
| Viability of Placental Organoids | Measurement of cell proliferation rate in normal and pathological placental organoids before and after anticoagulant, anti-inflammatory, and immunomodulatory treatments (heparin, aspirin, metformin, IVIg, filgrastim). Assessment Parameters: Cell viability (live/dead staining) | From date of caesarean section until the development of placental organoids, until 36 months |
| Measure | Description | Time Frame |
|---|---|---|
| Gene Expression in Placental Organoids | Quantification of tissue-specific gene expression in normal and pathological placental organoids before and after treatments. Assessment Parameters: Differential expression of target genes (qPCR) | From date of caesarean section until the development of placental organoids, until 36 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Women with normal pregnancy (n=5) or complicated by:
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chiara Tersigni | Contact | +390630157546 | chiara.tersigni@policlinicogemelli.it |
| Name | Affiliation | Role |
|---|---|---|
| Chiara Tersigni, MD | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ostetricia e Patologia Ostetrica | Rome | Lazio | 00168 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| D047928 | Premature Birth |
| ID | Term |
|---|---|
| D046110 | Hypertension, Pregnancy-Induced |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Secretome Analysis of Placental Organoids |
Analysis of extracellular vesicles and soluble factors secreted by placental organoids before and after treatments. Assessment Parameters: Quantification of cytokines by ELISA assay |
| From date of caesarean section until the development of placental organoids, until 36 months |
| Proliferative Capacity of Placental Organoids | Assessment of percentage of proliferating cells | From date of caesarean section until the development of placental organoids, until 36 months |
| Growth capacity of placental organoids | Assessment of organoid growth rate (diameter increase over time). | From date of caesarean section until the development of placental organoids, until 36 months |
| Protein expression in placental organoids | Assessment of differential expression of proteins by Western blot, immunohistochemistry. | From date of caesarean section until the development of placental organoids, until 36 months |
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |